Serina Therapeutics (SER) AI Stock Analysis

• Market Cap: $18.12M
• Dividend Yield: N/A
• Average Volume (3M): 24.47K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.08
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 10,785,564
• 10 Day Avg. Volume: 14,098
• 30 Day Avg. Volume: 24,472
• PEG Ratio: <0.01
• Price to Book (P/B): 57.52
• Price to Sales (P/S): 658.37
• P/FCF Ratio: -2.15
• Enterprise Value/Market Cap: 0.67
• Enterprise Value/Revenue: 103.89
• Enterprise Value/Gross Profit: 182.60
• Enterprise Value/Ebitda: -0.65
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $2.50 ▲(48.81% Upside)

The score is weighed down primarily by weak financial performance (large ongoing losses and significant cash burn with limited equity cushion), compounded by a negative listing-compliance event that raises uncertainty. Technicals provide a partial offset due to improving short-term momentum, but valuation is constrained by negative earnings and no dividend support.

Positive Factors

Pipeline advancement - SER-252 IND clearance

IND clearance for SER-252 enables initiation of a Phase 1b registrational study in advanced Parkinson’s, materially derisking that program. Over months this progresses clinical development, supports future partnering or funding milestones, and enhances the company’s long-term pipeline value.

Manageable leverage

Reported low debt relative to assets provides financing flexibility and reduces immediate insolvency risk. For a development-stage biotech, manageable leverage preserves optionality to pursue R&D and partnerships without near-term debt pressure, sustaining operations while clinical programs advance.

Proprietary drug-delivery tech and partnership potential

Ownership of proprietary delivery technology plus therapeutic programs creates multiple commercial and collaboration pathways. Durable advantages include licensing, milestone/royalty inflows and attractiveness to larger pharma, which can provide non-dilutive funding and accelerate commercialization timelines.

Negative Factors

Substantial cash burn

Deeply negative operating and free cash flow indicate ongoing high funding needs. Over the coming months this heightens reliance on external financing or partners, raises dilution risk, and may force reprioritization of programs if new capital or revenue sources aren’t secured.

Thin shareholders' equity and NYSE compliance risk

Very low reported equity and a formal NYSE deficiency notice create structural listing and financing uncertainty. The required remediation plan and cure period increase governance and capital-raising pressure, potentially constraining access to markets and forcing dilutive financings or strategic concessions.

Revenue instability and persistent losses

Small, declining revenues combined with recurring operating losses reflect weak commercial traction and earnings instability. This undermines the company’s ability to self-fund development, increases dependence on external capital or partnerships, and elevates execution risk over months.

Serina Therapeutics Business Overview & Revenue Model

Company Description

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

How the Company Makes Money

Serina Therapeutics generates revenue primarily through the commercialization of its proprietary drug delivery technologies and therapeutic products. The company may also engage in strategic partnerships and collaborations with larger pharmaceutical firms, which can provide upfront payments, milestone payments, and royalties on future sales. Additionally, research grants and funding from government agencies or private investors focused on innovative medical treatments contribute to its financial resources. The success of clinical trials and the approval of its products can significantly impact its revenue streams, as successful therapies move into the market.

Serina Therapeutics Financial Statement Overview

Summary

Financial profile is weak: TTM results are heavily loss-making with very small revenue versus expenses, substantial operating losses, and deep negative operating/free cash flow indicating significant cash burn. While leverage is currently modest, equity has been thin/negative historically, increasing funding and dilution risk.

Income Statement

Results remain heavily loss-making in TTM (Trailing-Twelve-Months), with extremely negative profitability and a sizable operating loss relative to a very small revenue base. Revenue is also down versus the prior period, and margins have swung sharply over time (including a one-off profitable year in 2023), pointing to limited earnings stability and high dependence on non-recurring items.

Balance Sheet

Leverage appears manageable in the most recent period, with low debt relative to equity in TTM (Trailing-Twelve-Months) and a larger asset base versus prior years. However, equity has been negative in multiple historical periods and remains relatively thin versus ongoing losses, which raises funding/dilution risk and reduces balance-sheet resilience.

Cash Flow

Cash burn is substantial, with operating and free cash flow deeply negative in TTM (Trailing-Twelve-Months), consistent with a development-stage biotech profile. While free cash flow has shown some improvement at times, cash generation is not yet self-sustaining and ongoing external financing is likely needed if burn persists.

Breakdown	TTM	Dec 2024	Dec 2023	Mar 2023	Dec 2021	Mar 2021
Income Statement
Total Revenue	116.00K	56.00K	3.15M	500.00K	3.04M	54.00K
Gross Profit	66.00K	-138.00K	3.06M	500.00K	3.04M	-1.23M
EBITDA	-18.49M	-10.49M	5.92M	-2.60M	-1.23M	-8.74M
Net Income	-18.59M	-11.14M	5.27M	-2.68M	-1.26M	-10.87M
Balance Sheet
Total Assets	12.41M	6.72M	8.97M	3.24M	3.15M	3.92M
Cash, Cash Equivalents and Short-Term Investments	8.62M	3.67M	7.62M	645.00K	584.00K	527.00K
Total Debt	3.20M	268.00K	3.44M	18.12M	13.20M	6.30M
Total Liabilities	10.82M	6.22M	41.26M	20.56M	15.03M	9.32M
Stockholders Equity	1.76M	641.00K	-32.29M	-17.21M	-11.83M	-5.12M
Cash Flow
Free Cash Flow	-16.53M	-17.16M	-2.98M	-2.09M	-2.36M	-7.84M
Operating Cash Flow	-16.51M	-17.14M	-2.48M	-2.08M	-2.25M	-7.82M
Investing Cash Flow	-64.00K	-22.00K	-504.00K	980.94K	823.32K	-20.00K
Financing Cash Flow	21.96M	13.21M	10.07M	1.31M	1.08M	5.96M

Serina Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Negative. The current price of 1.68 is below the 20-day moving average (MA) of 2.37, below the 50-day MA of 2.54, and below the 200-day MA of 4.52, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 33.52 is Neutral, neither overbought nor oversold. The STOCH value of 5.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SER.

Serina Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SKYE	49 Neutral	$25.08M	-0.60	-94.31%	―	―	-53.18%
SER	45 Neutral	$18.12M	-0.29	―	―	―	―
CELU	44 Neutral	$42.68M	-0.40	―	―	-15.81%	-113.06%
BRNS	44 Neutral	$26.95M	-0.31	-62.30%	―	-100.00%	-26.30%
OTLK	39 Underperform	$34.02M	-0.40	―	―	―	86.28%

Serina Therapeutics Corporate Events

Serina Therapeutics Faces NYSE American Compliance Deficiency Notice

On January 9, 2026, Serina Therapeutics received a deficiency notification from NYSE American stating the company is not in compliance with the exchange’s minimum stockholders’ equity requirements, after reporting equity of $1.6 million as of September 30, 2025 and losses in three of its four most recent fiscal years ended December 31, 2024. Serina has until February 8, 2026 to submit a remediation plan outlining actions to regain compliance by July 9, 2027, during which its shares will continue trading on NYSE American with enhanced oversight; acceptance of the plan would allow the company to remain listed through the cure period, while rejection would trigger delisting proceedings, creating added uncertainty for shareholders even as the company’s day-to-day operations and SEC reporting obligations remain unaffected in the near term.

The most recent analyst rating on (SER) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.

Serina Therapeutics Holds 2025 Annual Stockholders Meeting

On November 7, 2025, Serina Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders. During the meeting, Steve Ledger and Karen J. Wilson were elected as directors to serve until the 2028 Annual Meeting. Additionally, the appointment of Frazier & Deeter, LLC as the company’s independent auditors for the 2025 fiscal year was ratified. The issuance of common stock related to the Convertible Note and Warrants was also approved.

The most recent analyst rating on (SER) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.